Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy

HER2 (ERBB2) amplification is a driving oncogenic event in breast cancer. Clinical trials have consistently shown the benefit of HER2 inhibitors (HER2i) in treating patients with both local and advanced HER2+ breast cancer. Despite this benefit, their efficacy as single agents is limited, unlike the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proc Natl Acad Sci U S A
Hauptverfasser: Floros, Konstantinos V., Lochmann, Timothy L., Hu, Bin, Monterrubio, Carles, Hughes, Mark T., Wells, Jason D., Morales, Cristina Bernadó, Ghotra, Maninderjit S., Costa, Carlotta, Souers, Andrew J., Boikos, Sosipatros A., Leverson, Joel D., Tan, Ming, Serra, Violeta, Koblinski, Jennifer E., Arribas, Joaquin, Prat, Aleix, Paré, Laia, Miller, Todd W., Dozmorov, Mikhail G., Harada, Hisashi, Windle, Brad E., Scaltriti, Maurizio, Faber, Anthony C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: National Academy of Sciences 2018
Schlagworte:
PNAS Plus
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5856537/
https://ncbi.nlm.nih.gov/pubmed/29476008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1717820115
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge